Liberty Star’s Hay Mountain Project Shines Spotlight on Arizona Critical Minerals; DC Advocacy Accelerates Government Awareness TUCSON, AZ, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Liberty Star Minerals ( or the ) () is proud to highlight the renewed national focus on its flagship Hay Mountain Project in Cochise County, Arizona—a property now recognized as a cornerstone for America’s critical mineral ambitions. This builds on a surge of exploration momentum and a successful Washington, DC advocacy campaign in May led by Board Chairman Pete O’Heeron. Congressional Support: Gosar’s Letter to Cabi...
Liberty Star Embarks on 3D IP Survey at Red Rock Gold Project, SE Arizona TUCSON, AZ, June 30, 2025 (GLOBE NEWSWIRE) -- Liberty Star Minerals ( or the ) () is pleased to announce the launch of a state-of-the-art 3D induced polarization survey (“3D IP Survey,” “Survey”) at its wholly owned Red Rock Canyon Gold Project (RRC), part of the Hay Mountain Project in southeast Arizona. The Survey aims to be the next initiative to unlock the immense potential of RRC, which is believed to host commercially significant metals associated with epithermal gold mineralization, a hallmark of the minera...
Liberty Star Announces Successful SAM Registration, Enhancing Opportunities for Federal Grants TUCSON, AZ, June 02, 2025 (GLOBE NEWSWIRE) -- Liberty Star Minerals (OTCQB: LBSR), a U.S.-based exploration company focused on strategically vital critical minerals, announced today its successful registration with the System for Award Management (SAM), the federal government’s central platform for contract and grant eligibility. This isn’t just a check-the-box achievement—it’s a strategic move that expands our access to federal funding opportunities, positioning Liberty Star to contribute dire...
Lockout Rally in Full Swing Continuing the trend from last week's U.S. Macro Vision (4/29/25), we are seeing more and more signs that lead us to believe the S&P 500 (SPX) made a major bottom at 4800-4820, which is where we initially discussed in our 4/8/25 Compass to look for a local bottom to develop. As a result, we have been short-term bullish since our 4/22/25 Compass, when we noted that the SPX was testing 5100-5120 support, a potential bounce spot and a level to trade long against. With t...
Liberty Star Board Chair Pete O’Heeron & Director Gerardo King Interviewed by Steve Darling of Proactive Investors Limited TUCSON, AZ, April 16, 2025 (GLOBE NEWSWIRE) -- Liberty Star Minerals ( or the ) () is executing on a vision that aligns with the long-term strategic needs of the United States. In a recent conversation with award-winning broadcaster Steve Darling of Proactive Investors, Board Chair Pete O’Heeron and Director Gerardo King shared why critical mineral development is no longer optional—it’s essential. Pete O’Heeron recently returned from Washington, D.C., where he held h...
Liberty Star Minerals Chairman Pete O’Heeron Engages with Congressional Leaders in D.C. to Champion U.S. Critical Mineral Independence TUCSON, AZ, April 10, 2025 (GLOBE NEWSWIRE) -- Liberty Star Minerals ( or the ) (), a U.S. exploration company focused on strategic and commercially important critical minerals, today announced that Chairman of the Board Pete O’Heeron traveled to Washington, D.C. this week for a series of high-level meetings with Congressional offices to discuss the urgent need for U.S. investment in the exploration and development of critical minerals. While in the natio...
Greenwich LifeSciences Provides Global Update on FLAMINGO-01 STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date & Future Plans The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trendi...
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label immune response data. FLAMINGO-01 Immune Response Data Summary The Company has analyzed the preliminary immune response data from ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.